As the population ages, the number of end-stage heart failure patients requiring heart transplantation is increasing. An inadequate number of donor hearts to support this need has led to mortality rates of up to 30% in patients waiting for transplant. 1 This has necessitated the use of left ventricular assist devices (LVADs) not only as a treatment leading up to heart transplantation but also as an alternative treatment for myocardial and hemodynamic recovery or as permanent support in nontransplant candidates. Technological advances in the development of LVADs have increased their use in many end-stage heart failure patients. Some devices allow the patient to be completely ambulatory and live at home. Although LVAD technology is improving, there are risks and complications. Echocardiography can be used to detect complications and assist in the management of patients with LVADs. Echocardiography is used to aid in the selection of LVAD candidates by providing necessary information to determine whether LVAD implantation will provide hemodynamic benefit to the patient. Intraoperative transesophageal echocardiography is vital during the implantation of the LVAD to assess LVAD function and the hemodynamic response to LVAD placement.
LVAD Types and Mechanics
Currently, there are 4 types of LVADs available: ABIOMED BVS 5000 (Abiomed, Danvers, MA), Thoratec (Thoratec Laboratories, Berkeley, CA), Novacor LVAS (Baxter Healthcare Corporation, Oakland, CA), and HeartMate (Thermo Cardiosystems, Woburn, MA). All 4 systems are similar in components that consist of a pump, inflow and outflow cannulae, and a power source ( Fig. 1 ). LVAD function among each device is also similar. Blood exits the left or right heart via the inflow cannula and enters the pump. Blood is then forced out of the pump into the outflow cannula connected to the 2 great vessels that direct blood to either the ascending aorta or the lungs Table 1 gives an overview of the similarities and differences of the 4 types of LVADs.
Risks and Complications
Bleeding, right-sided heart failure, air embolism, and progressive multisystem organ failure are the most common causes of early morbidity and mortality in patients with LVADs. 2 Bleeding can be due to preoperative coagulopathy as a result of hepatic dysfunction, poor nutritional status, antibiotic medications, cardiopulmonary bypass induced thrombocytopenia, and the extensive nature of the device implantation surgery. Right-sided heart failure can occur as a result of an increased demand on the right heart to maintain adequate pressures necessary for proper device function. Other potential complications are thromboembolism, infection, device malfunction, and hemolysis. Thromboembolic events are less in patients with HeartMate devices due to the textured lining of the HeartMate, which promotes neointima formation. 3 This minimizes thrombus development and bacterial colonization. 3 Investigators report that this type of surface may be responsible for the low thromboembolic risk associated with this device despite the avoidance of systemic anticoagulation. 4 Infection, most commonly arising from the drive line exit site, can occur in a number of patients. In a study of more than 2000 patients in 73 centers worldwide, clinically significant infections related to LVAD placement occurred in 25%. 5
Role of Echocardiography
The role of echocardiography in the evaluation of LVAD patients continues to expand. Echocardiography is used not only to detect possible complications but also to evaluate improvements in left ventricular function.
PREOPERATIVE, INTRAOPERATIVE, POSTOPERATIVE EVALUATION
A recent review by Scalia et al. 6 described the role of echocardiography preoperatively, intraoperatively, postoperatively, and during late follow-up. Their clinical echocardiographic approach, developed over experience with 91 assist patients, implanted with the HeartMate IP and VE models, describes the clinical impact of specific anatomic, physiologic, hemodynamic, and mechanical features.
The preoperative assessment of anatomic and physiologic abnormalities is important in order to prevent possible complications during or after LVAD insertion. This preoperative assessment can include evaluating presence of a possible patent foramen ovale, aortic regurgitation, right ventricular function, tricuspid regurgitation, intracavitary thrombus, aortic atheroma, and mitral regurgitation. Assessment can be done by transthoracic echocardiography imaging and more commonly by intraoperative transesophageal echocardiography. Diagnosis of a patent foramen ovale by a saline contrast injection can be used to detect right-to-left shunting that leads to increased risk of embolism. The presence and severity of aortic regurgitation preoperatively is important because of the high aorta-to-left ventricle gradient with LVAD operation. The aortic valve, which remains closed with LVAD use (Fig. 3 ), must constantly withstand this gradient, and therefore patients can only have minimal or no evidence of aortic regurgitation. If present preoperatively, aortic regurgitation can worsen postoperatively and may lead to high preload conditions that the pump cannot handle. Preserved right ventricular function is critical for proper LVAD function because the device is dependent on high left ventricular and left atrial pressures that are determined by normal right ventricular function. Tricuspid regurgitation, intracavitary thrombus, aortic atheroma, and mitral regurgitation should all be documented, as these can also affect outcomes following LVAD insertion.
The intraoperative role of transesophageal echocardiography can be employed for assessment of the de-airing of the pump, LVAD function, inlet cannula position, and presence of a patent foramen ovale. Transesophageal echocardiography is used during the de-airing of the pump to monitor the amount of air bubbles released into the ascending aorta after the clamp is removed from the outflow conduit. Once the de-airing procedure is complete, transesophageal echocardiography is used to determine whether the LVAD is properly operating by assessment of right ventricular function. If right ventricular dysfunction occurs, the right heart dilates and leads to a decrease in left heart inflow with decreases in left-sided filling pressures. This may cause dual chamber collapse. Transesophageal echocardiography can be used to ensure the proper placement of the inflow conduit and whether it is centrally located in the left ventricular apex. The lack of proper conduit placement will lead to inflow obstruction from adjacent walls. This will be demonstrated by turbulent flow with color Doppler and by high-velocity flows within the inflow conduit shown by pulsed Doppler. In unobstructed inflow conduits, the peak filling velocities are below 2.3 m/s. Obstructed inflow conduits, which required repositioning, had peak filling velocities above 2.5 m/s. 6 Reassessment of a patent foramen ovale after device activation is necessary should a patent foramen occur and result in a decrease in the patient's oxygen saturation levels.
Postoperative echocardiography is generally used for detection of possible device malfunction. The diagnosis can include hypovolemia, right ventricular failure, inflow conduit obstruction, cardiac tamponade, outflow conduit obstruction, and pulmonary embolus, all of which can be detected by echocardiography. Transesophageal echocardiography is the preferred imaging method postoperatively because of poor transthoracic echocardiographic windows in these patients. Echocardiography can be used to determine causes of high pump flow rates by comparing right-sided cardiac output to device output. High biventricular flow rates suggest sepsis. However, high LVAD flow rates as compared to right-sided flow rates indicate possible LVAD volume overload. LVAD volume overload can be caused by aortic regurgitation and if not present preoperatively could suggest aortic valve endocarditis. LVAD volume overload can also occur by regurgitation of the device system's inflow and outflow valves. Pulsed Doppler can be employed to detect regurgitation of the inflow valve by placing the sample volume within the inflow conduit. Outflow valve regurgitation can be determined using a right parasternal window to image the outflow conduit for placement of the Doppler sample volume. Transesophageal echocardiography may also be used to rule out thrombus prior to cardioversion in LVAD patients who develop atrial fibrillation. It is routine practice to use transesophageal echocardiography during LVAD removal for possible air entrapment and subsequent ejection into the aorta as a result of possible micro-perforation during removal of the inlet conduit.
The review by Scalia et al. 6 provides a thorough discussion of the role of echocardiography surrounding LVAD usage and summarizes 4 studies 7-10 written in the early 90s. The strength of Scalia et al.'s study was its large sample size. However, the study was limited to include patients only on HeartMate devices. Because of the various insertion locations of inlet and outlet conduits of the other LVAD models (BVS 5000 and Thoratec), it would be of value to compare possible differences in device function.
Akosah et al. 11 reviewed the role of echocardiography in patients with LVADs and postoperative evaluation, specifically device function or malfunction. The study's aim was to evaluate the echocardiographic parameters of a normally functioning LVAD and to determine the distinguishing features of non-device-related problems compared to device malfunction. The study group consisted of 18 patients implanted with HeartMate devices. Transesophageal echocardiography was used intraoperatively prior to and immediately after insertion of the device to document chamber dimensions, valvular flow, left ventricular and right ventricular diameters, inlet cannula diameter, and inlet cannula flow. Postoperatively, serial echocardiographic examinations were performed by transthoracic imaging in stable patients and by transesophageal echocardiography in unstable patients whose transthoracic echocardiography study was nondiagnostic. Serial studies provided data with regard to persistent aortic valve opening or flow, presence of aortic regurgitation, inflow characteristics, pulmonic flow, and right and left ventricular dimensions.
Patients were categorized into 3 groups. Patients in group 1 (n = 9) were clinically and hemodynamically stable during the course of the study. Patients in group 2 (n = 3) were clinically unstable due to mechanical problems with the device and required surgical intervention. Patients in group 3 (n = 6) included patients who were clinically unstable, but for reasons other than device malfunction. Serial echocardiographic findings in group 1 demonstrated no evidence of aortic valve opening or flow across the aortic valve. Color Doppler demonstrated laminar flow directed into the cannula at the apex (Fig. 4) . Doppler-derived cardiac output obtained at the pulmonic valve matched the output of the device. Serial echocardiographic findings in group 2 disclosed either persistent or occasional aortic valve opening, forward flow across the aortic valve, and aortic insufficiency (Fig. 5 ). The inlet cannula was positioned incorrectly toward the septum in 2 patients. Color Doppler showed high-velocity mosaic turbulent pattern in the left ventricle. Comparison of the Doppler-derived right-sided cardiac output did not match the output of the device. All patients in group 2 had device malfunction determined by surgical intervention. Serial echocardiographic examinations in group 3 showed matched but low cardiac output of the LVAD and, by Doppler, of the pulmonic valve. Doppler flow in the left ventricle was laminar, and there was no evidence of either aortic valve opening or aortic valve flow. Clinical instability in this group was due to right ventricular failure in 3 patients, cardiac tamponade in 1 patient, ventricular fibrillation in 1 patient, and sepsis in 1 patient.
The ventricular apex. Patients who, by echo, demonstrated aortic valve opening, flow, or regurgitation; discrepancy between right-sided cardiac outputs to the device output; or turbulent flow in the left ventricle (due to improper cannula alignment) were all highly suggestive of having a malfunctioning LVAD. Lack of these findings is consistent with proper device function in both clinically stable patients and in patients with instability due to complications other than LVAD malfunction. A limitation of Akosah et al.'s 11 study was its small patient population (N = 18). Of the 18 patients studied, only 3 had device malfunction, which is a small number to generalize the study's conclusion. The method of evaluation included transthoracic echocardiography in stable patients, whereas transesophageal echocardiography was used in unstable patients for whom transthoracic echocardiography was nondiagnostic. Transthoracic echocardiography and transesophageal echocardiog-raphy may not have provided comparable results. The presence of aortic valve opening or flow could suggest device malfunction. However, aortic valve opening or flow can also be an indication of aortic valve pathology, specifically of infective endocarditis. Therefore, aortic valve opening or flow is not specific to device malfunction; nonetheless, it can lead to device malfunction.
George et al. 12 proposed a routine of intraoperative transesophageal echocardiography evaluation during LVAD implantation in 3 stages: (1) after induction and before cardiopulmonary bypass (CPB), (2) before weaning from CPB, and (3) after bypass. Prior to CPB, transesophageal echocardiography was used to detect the presence of an atrial septal defect or patent foramen ovale, to assess right ventricular function, to assess tricuspid and aortic valve competence, and to detect thrombi in the cardiac chambers or ascending aorta. Prior to discontinuing CPB, transesophageal echocardiography was used to assess the proper placement of the inflow cannula, to detect air emboli or air entrapment and entrainment, and to assess adequate right and left ventricular volumes. Following CPB, transesophageal echocardiography provides an assessment of right ventricular function, detection of air embolism, a documentation of device flows and cardiac output (by the use of Doppler), and a confirmation of aortic valve competence and continuous closure.
George et al. 12 described various roles of echocardiography in the operating room, similar to the roles described by Scalia et al. 6 and Akosah et al. 11 and similar to the roles, specifically of intraoperative transesophageal echocardiography, that have been described in previous studies. [13] [14] [15] [16] Buckland et al. 17 focused specifically on methods of intraoperative transesophageal echocardiography evaluation based on experience with patients with Thoratec systems. In a case report, the authors described a situation in which the patient had a left ventricular thrombus, making inflow cannula insertion into the apex difficult. As a result, the inflow cannula was sewn into the left atrium, a capability unique to the Thoratec and BVS 5000 devices. The discussion focused on how transesophageal echocardiography should be used in this setting, the strengths and limitations of epicardial echocardiography, and the strengths and limitations of transesophageal echocardiography. Buckland et al. highlighted specific features that should be addressed by transesophageal echocardiography, including the presence of intracavitary thrombi, a patent foramen ovale, intracardiac air, correct positioning of the apical cannula, and an appropriate ventricular response to device initiation. Also, color Doppler should be used to demonstrate direction and velocity of blood through valves and possible shunts, such as a patent foramen ovale. The limitations of epicardial echocardiography include (1) its need for direct application on the heart, which necessitates a sterile sheath and can interrupt surgery, causing limitations in image acquisition, and (2) the possibility of arrhythmias or cardiac damage due to the pressure of the probe. The strengths of epicardial echocardiography are the ability to generate high-quality images, multiple scanning planes, and proper blood flow measurements, as well as the ability to remove and move the probe easily. The strengths of transesophageal echocardiography include more scanning time available because of the lack of interruption of the surgery or interference with the sterile field and the production of good quality images. The limitations of transesophageal echocardiography are the presence of fewer tomographic imaging planes (which has been improved by multiplanar probes), the difficulty encountered with imaging during electrocautery, and the lack of continuous wave Doppler, which is available with modern transesophageal echocardiography probes.
The feature that sets this study apart from other studies is its basis on patients with Thoratec devices rather than on patients with a HeartMate. It is also interesting to see the early developments of transesophageal echocardiography and LVAD evaluation.
EVALUATION OF LEFT VENTRICULAR STRUCTURE AND FUNCTION
More recently, research has been directed at the change in left ventricular function as a result of myocardial recovery during use of an LVAD and after subsequent removal of the device. McCarthy et al. 18 reported the structural and histologic changes of the left ventricle before and after a HeartMate device insertion (mean duration of support = 76 ± 34 days) to determine myocardial recovery. Transesophageal echocardiography was used intraoperatively to evaluate the left ventricular structural changes prior to LVAD insertion, immediately after, and during removal at the time of heart transplantation. Histologic studies were performed on the portion of the left ventricular apex removed for the inflow conduit attachment and the explanted heart at transplantation.
Results from transesophageal echocardiography evaluation disclosed an immediate decrease in left ventricular dimensions after device insertion that remained consistent at the time of explantation. There was no significant change in fractional shortening immediately after implantation or at explantation. Measurements of left ventricular wall thickness were not provided. Histologic examination comparing preand post-LVAD implantation myocardium revealed a decrease in the number of wavy fibers and contraction band necrosis and an increase in fibrosis. There was no significant change in myocyte diameter. McCarthy et al. 18 suggested that although there was an immediate decrease in left ventricular size, this finding does not indicate "recovery"; rather, the finding indicates a change in loading conditions. The absence of increase in left ventricular fractional shortening is also dependent on loading conditions and should not be used alone as a primary indication of function. Histologic markers of acute myocyte damage improve, but fibrosis increases.
In another study from the same group, it was proposed that despite no evidence of myocardial recovery, LVAD insertion might have a role in "resting" the ventricle for selected patients with endstage heart failure. 19 Nakatani et al. 20 published a report on LVAD effects of left ventricular unloading and left ventricular diastolic filling. Intraoperative transesophageal echocardiography was used in 8 patients implanted with a HeartMate device. Measurements were made before CPB and device insertion and after device insertion when the patient had been weaned off of CPB. Pulsed Doppler measurements included peak velocities of early diastolic filling (E wave), late diastolic filling (A wave), late to early filling ratio (A/ E ratio), deceleration time of early filling (DT), and diastolic filling period (DFP) corrected by the R-to-R interval. All measurements were obtained in 10 consecutive beats. The severity of mitral regurgitation and left atrial and left ventricular size were measured.
The pulsed Doppler transmitral inflow velocities changed after device implantation. Pre-CPB implantation, all patients demonstrated either a restrictive (E wave > A wave) or a monophasic (only an E wave) transmitral flow pattern, with shortened DT. After insertion, all patients demonstrated beat-tobeat variation in transmitral flow, continuously changing from an abnormal relaxation pattern (E wave < A wave) to a restrictive pattern. However, when the values taken from the 10 consecutive beats were averaged, transmitral flow seemed to show a pattern of decreased early filling and increased late filling with a prolonged DT and DFP. The degree of mitral regurgitation decreased in severity, as did left atrial and left ventricular dimensions.
Nakatani et al. 20 concluded that the beat-to-beat variation seen after device insertion was a result of variable loading conditions due to lack of synchronization between the pumping cycle of the device and the pumping cycle of the heart. This asynchronization occurs when the device is set in an automatic mode, in which the pump compresses once the filling chamber is 90% full, and was used in the study data acquisition. Therefore, the timing of the device cycle must be considered when determining diastolic function from transmitral inflow patterns. It is not clear why there was a more consistent pattern of transmitral flow (E wave < A wave and a longer DT and DFP) when 10 consecutive beats were averaged. This pattern may occur during treatment of patients with congestive heart failure as a result of a decrease in filling pressure and a reduction in left ventricular operating stiffness. 21
Conclusion
Echocardiography has proven to be essential in the preoperative, intraoperative, and postoperative stages of LVAD management and is gaining importance in the evaluation of myocardial functional recovery. Future directions with regard to the role of echocardiography may include the use of intracardiac ultrasound to provide a different, and more detailed, evaluation of patients with LVADs. As LVADs become permanently implanted in patients who are not candidates for transplant, echocardiography will be of importance in the long-term follow-up of these patients. It will also be of interest to determine the chronic changes in cardiac function of patients with permanently implanted devices. Although permanent support with an LVAD has not yet evolved, there is a growing number of patients discharged from the hospital while on a portable LVAD. Because of this situation, an exam protocol specific to these patients should be established.
